Transaction DateRecipientSharesTypePriceValue
8th January 2021Advisors Llc Perceptive347,332Open or private purchase$9.21$3,198,927.72
8th January 2021Advisors Llc Perceptive152,668Open or private purchase$10.21$1,558,740.28
8th January 2021Advisors Llc Perceptive50,000Open or private purchase$7.60$380,000.00
7th January 2021Advisors Llc Perceptive500,000Open or private purchase$8.13$4,065,000.00
23rd November 2020Advisors Llc Perceptive500,000Open or private purchase$12.85$6,425,000.00
17th November 2020Martha J Demski7,042Exercise of derivative$2.35$16,548.70
17th November 2020Martha J Demski7,042Bona fide gift$0.00
17th November 2020Martha J Demski7,042Bona fide gift$0.00
27th October 2020Advisors Llc Perceptive3,000,000Open or private purchase$10.00$30,000,000.00
21st October 2020Advisors Llc Perceptive43,195Open or private purchase$10.09$435,837.55
Adma Biologics
Adma Biologics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.

Ticker: ADMA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1368514
Employees: 318
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Common Stock, Shares, Issued: $86 M (45%)